Abstract
Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13%), fatigue (13%), peripheral neuropathy (10%), and neutropenia (7%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.
| Original language | English |
|---|---|
| Article number | 578 |
| Journal | Cancers |
| Volume | 11 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2019 |
Fingerprint
Keywords
- Colorectal cancer
- Doublet chemotherapy
- Elderly patients
- Oxaliplatin
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years : A post-hoc subgroup analysis of three phase ii trials. / Rosati, Gerardo; Cordio, Stefano; Reggiardo, Giorgio; Aprile, Giuseppe; Butera, Alfredo; Avallone, Antonio; Tucci, Aniello; Novello, Giuseppe; Blanco, Giuseppina; Caputo, Giuseppe; Bilancia, Domenico; Bordonaro, Roberto.
In: Cancers, Vol. 11, No. 4, 578, 01.04.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer aged at least 75 years
T2 - A post-hoc subgroup analysis of three phase ii trials
AU - Rosati, Gerardo
AU - Cordio, Stefano
AU - Reggiardo, Giorgio
AU - Aprile, Giuseppe
AU - Butera, Alfredo
AU - Avallone, Antonio
AU - Tucci, Aniello
AU - Novello, Giuseppe
AU - Blanco, Giuseppina
AU - Caputo, Giuseppe
AU - Bilancia, Domenico
AU - Bordonaro, Roberto
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13%), fatigue (13%), peripheral neuropathy (10%), and neutropenia (7%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.
AB - Patients older than 75 years of age are usually excluded from metastatic colorectal cancer studies based on a combination chemotherapy containing oxaliplatin. Our group conducted three phase II trials in elderly patients in recent years. A post-hoc subgroup analysis of 67 patients aged at least 75 years was included in this study. Oxaliplatin was combined with capecitabine in two trials and with uracil-tegafur (UFT) plus folinic acid in the third trial. In one study, bevacizumab was also added to chemotherapy. The median age of patients was 77 years, and all had a good performance status (0 to 1). The observed overall response rate was 45%, comparable to younger patients (51%, p = 0.49). The estimated median progression-free survival (PFS) time and overall survival (OS) time were 8.7 and 19.3 months, respectively. These results did not significantly differ from those in younger patients (8.0 months for PFS (p = 0.58) and 19.7 months for OS (p = 0.94), respectively). The most common grade 3–4 adverse events included diarrhea (13%), fatigue (13%), peripheral neuropathy (10%), and neutropenia (7%). Moreover, the toxicity was never statistically different from that in younger patients. The efficacy of oxaliplatin-based combination was maintained in fit elderly patients ≥75 years.
KW - Colorectal cancer
KW - Doublet chemotherapy
KW - Elderly patients
KW - Oxaliplatin
UR - http://www.scopus.com/inward/record.url?scp=85065424369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065424369&partnerID=8YFLogxK
U2 - 10.3390/cancers11040578
DO - 10.3390/cancers11040578
M3 - Article
AN - SCOPUS:85065424369
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 4
M1 - 578
ER -